Skip to main content
SpringerLink
Log in

Strategies To Stabilize Dalbavancin in Aqueous Solutions; Section 3: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Phosphate Buffer with and without Divalent Metal Ions

  • Original Research Article
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose

New formulations of the glycopeptide drug dalbavancin containing 2-hydroxpropyl-β-cyclodextrin (2HPβCD) with or without divalent metal ions in phosphate buffer (pH 7.0) were tested to evaluate whether these excipients influence the aqueous solution stability of dalbavancin.

Method

Recovery of dalbavancin from phosphate buffered solutions at pH 7.0 with different concentrations of 2HPβCD and a divalent metal ion (Ca2+, Mg2+, or Zn2+) was evaluated by RP-HPLC and HP-SEC after four weeks of storage at 5°C and 55°C. A long-term study of formulations with 2HPβCD and Mg2+ was carried out over six months at 5°C, 25°C, and 40°C using RP-HPLC.

Results

Dalbavancin solutions with either 5.5 mM or 55 mM 2HPβCD were significantly more stable with Mg2+ than with the other divalent metal ions, both at 55°C for four weeks and at 40°C for six months. Dalbavancin was found to be more stable in aqueous solutions at a concentration of 1 mg/mL than at 20 mg/mL with 2HPβCD and Mg2+ at 40°C for six months.

Conclusion

The results suggest that 2HPβCD forms an inclusion complex with dalbavancin that slows the formation of the major degradant, mannosyl aglycone (MAG). The effect of 2HPβCD is increased in the presence of Mg2+ and phosphate at pH 7.0, and the complex is more stable at a dalbavancin concentration of 1 mg/mL than at 20 mg/mL. These observations point towards the possibility of formulating a dalbavancin injection solution with a long shelf life at room temperature and physiological pH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Data Availability

All data generated or analysed during this study are included in this published article.

References

  1. European Medicine Agency. Cyclodextrins Used as Excipients 2017 [Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf. Accessed 29 Mar 2023.

  2. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62:1607–21.

    Article  CAS  PubMed  Google Scholar 

  3. Stogniew M, Colombo L, Ciabatti R. Dalbavancin compositions for treatment of bacterial infections. US-8143212-B2 (Patent). 2012.

  4. Usach I, Martinez R, Festini T, Peris J-E. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019;36:2986–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544–75.

    Article  PubMed  Google Scholar 

  6. Avanti C, Amorij J-P, Setyaningsih D, Hawe A, Jiskoot W, VIsser J, et al. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. AAPS J. 2011;13(2):284–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jakaria SM, Budil DE, Murtagh J. Glycopeptide antibiotic drug stability in aqueous solution. AAPS Open. 2022;8(1):20.

    Article  PubMed  PubMed Central  Google Scholar 

  8. DALVANCE, Dalbavancin injection, powder, lyophilized for solution [package insert]: Durata Therapeutics Inc; 2014 [Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b4674d8-4d1e-4728-8465-d42ada33fa5c. Accessed 29 Mar 20223.

  9. Grimm W. Extension of the International Conference on Harmonization Tripartite Guideline for Stability Testing of New Drug Substances and Products to countries of climatic zones III and IV. Drug Dev Ind Pharm. 1998;24:313–25.

    Article  CAS  PubMed  Google Scholar 

  10. Zhu XF, Tan W, Zhou F, Li Z, Duan L. The effect of phosphate buffer solutions on uniconazole complexation with hydroxypropyl-β-cyclodextrin and methyl-β-cyclodextrin. J Incl Phenom Macrocycl Chem. 2011;73:193–8.

    Article  Google Scholar 

  11. Uekama K, Fujinaga T, Hirayama F, Otagiri M, Kurono Y, Ikeda K. Effect of cyclodextrins on the acid hydrolysis of digoxin. J Pharm Pharmacol. 1982;34:627–30.

    Article  CAS  PubMed  Google Scholar 

  12. Takashi S, Shunji H, Takashi Y, Yoichi K, Hirotsu K, Tsuneji N. Digoxin Degradation in Acidic Dissolution Medium. J Pharm Sci. 1980;69:410–3.

    Article  Google Scholar 

  13. Gault MH, Charles JD, Sugden DL, Kepkay DC. Hydrolysis of digoxin by acid. J Pharm Pharmacol. 1977;29:27–32.

    Article  CAS  PubMed  Google Scholar 

  14. Miyake K, Arima H, Hirayama F, Yamamoto M, Horikawa T, Sumiyoshi H, et al. Improvement of Solubility and Oral Bioavailability of Rutin by Complexation with 2-Hydroxypropyl-β-cyclodextrin. Pharm Dev Tech. 2000;5(3):399–407.

    Article  CAS  Google Scholar 

  15. Dechene EB. The relative stability of rutin and quercetin in alkaline solution. J Am Pharm Assoc. 1951;11:495–7.

    Article  Google Scholar 

  16. Kapešová J, Petrásková L, Markošová K, Rebroš M, Kotik M, Bojarová P, et al. Bioproduction of Quercetin and Rutinose Catalyzed by Rutinosidase: Novel Concept of “Solid State Biocatalysis". Int J Mol Sci. 2019;20:1112.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55:ii15–20.

    Article  CAS  PubMed  Google Scholar 

  18. Beauregard DA, Williams DH, Gwynn MN, Knowles DJ. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother. 1995;39:781–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hartl E, Winter G, Besheer A. Influence of Hydroxypropyl-Beta-Cyclodextrin on the Stability of Dilute and Highly Concentrated Imunoglobulin G Formulation. J Pharm Sci. 2013;102:4121–31.

    Article  PubMed  Google Scholar 

  20. Wang W, Martin-Moe S, Pan C, Musza L, Wang YJ. Stabilization of a polypeptide in non-aqueous solvents. Int J Pharm. 2008;351:1–7.

    Article  CAS  PubMed  Google Scholar 

  21. Ananthanarayanan VS, Belciug MP, Zhorov BS. Interaction of oxytocin with Ca2+: II. Proton magnetic resonance and molecular modeling studies of conformations of the hormone and its Ca2+ complex. Biopolym. 1996;40:445–64.

    Article  CAS  Google Scholar 

  22. Liu D, Seuthe AB, Ehrler OT, Zhang X, Wyttenbach T, Hsu JF, et al. Oxytocin-receptor binding: why divalent metals are essential. J Am Chem Soc. 2005;127:2024–5.

    Article  CAS  PubMed  Google Scholar 

  23. ICH Harmonised Tripartite Guideline; Stability Testing of New Drug Substance and Products Q1A(R2); Current Step 4 version 2003 [Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf. Accessed 29 Mar 2023.

Download references

Acknowledgements

This research work was supported by Hikma Pharmaceuticals.

Funding

The authors have received no payment for the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Hikma Pharmaceuticals, Bedford, OH-44146, USA

    Sardar M. Jakaria & James Murtagh

  2. Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA-02115, USA

    Sardar M. Jakaria & David E. Budil

Authors
  1. Sardar M. Jakaria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David E. Budil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Murtagh
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The authors confirm contribution to the paper as follows;

Research work was conducted in the lab, and the manuscript was prepared by Sardar M. Jakaria. David E. Budil and James Murtagh critically reviewed and revised the draft for intellectual content. All authors reviewed, edited, and approved the final version of the manuscript.

Corresponding author

Correspondence to Sardar M. Jakaria.

Ethics declarations

Conflict of Interest

The authors state no conflict of interest in preparation of this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jakaria, S.M., Budil, D.E. & Murtagh, J. Strategies To Stabilize Dalbavancin in Aqueous Solutions; Section 3: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Phosphate Buffer with and without Divalent Metal Ions. Pharm Res 40, 2027–2037 (2023). https://doi.org/10.1007/s11095-023-03525-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-023-03525-w

Keywords

Search

Navigation